USADA announced today that Deanna McGillivray of Albuquerque, N.M.,an athlete in the sport of team handball, has received a two-year sanction for an anti-doping rule violation.
McGillivray, 28, tested positive for trenbolone and its metabolite epitrenbolone as a result of an out-of-competition sample collected on December 13, 2014. Trenbolone and its metabolite are in the class of Anabolic Agents prohibited under the USADA Protocol for Olympic and Paralympic Movement Testing and the International Handball Federation Anti-Doping Regulations, both of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.
McGillivray’s period of ineligibility began on January 14, 2015, the date she received notice of her provisional suspension. In addition, McGillivray has been disqualified from all competitive results obtained on and subsequent to December 13, 2014, the date the sample was collected, including forfeiture of any medals, points and prizes.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.